Drug Profile
Research programme: COPD therapeutics - Redox Bioscience
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Redox Bioscience
- Class
- Mechanism of Action Oxidoreductase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in Japan
- 20 Jun 2006 Preclinical trials in Chronic obstructive pulmonary disease in Japan (unspecified route)